Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226466 · ClinicalTrials.gov registry record
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
A clinical trial, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- 40
- Enrollment target
NCT07226466 is a clinical trial that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT07226466 has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
Interventions
- PROCEDURE Blood sample
- PROCEDURE Brain magnetic resonance imaging (MRI)
- PROCEDURE Brain Health Assessment
- RADIATION Quality of Life (QoL) Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226466
The ClinicalTrials.gov registry entry for NCT07226466 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blood sample is the first listed.
NCT07226466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07226466 about?
NCT07226466 is a clinical study titled "Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer". This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological m...
What is the current status of trial NCT07226466?
This trial is currently not yet recruiting. The enrollment target is 40 participants. The study started on 2026-07-01. Estimated completion is 2028-10-31.
What interventions are being tested in trial NCT07226466?
The interventions under investigation include: Blood sample (PROCEDURE), Brain magnetic resonance imaging (MRI) (PROCEDURE), Brain Health Assessment (PROCEDURE), Quality of Life (QoL) Questionnaire (RADIATION).
Who is sponsoring clinical trial NCT07226466?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.